Astellas Reopens XLMTM Gene Trial After Deaths
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Astellas reenters the clinic with a next‑generation gene therapy for XLMTM after earlier trials caused deaths.
- Intellia reports its CRISPR treatment lonvo‑z cut hereditary angioedema attacks by 87% in a Phase 3 trial, with >60% of patients becoming attack‑free.
- Eli Lilly will acquire Ajax Therapeutics for up to $2.3 billion, adding a next‑generation JAK2 inhibitor in Phase 1 for myelofibrosis.
- Ligand Pharmaceuticals is buying Xoma for $739 million, expanding its drug‑royalty portfolio.
- Pfizer settled two of three patent cases on its ATTR‑CM drug Vyndamax, a move that lifted BridgeBio’s share price.
- Compass Therapeutics disclosed its advanced biliary cancer candidate slowed tumor growth but failed to improve survival versus chemotherapy.
Why it matters: Patients with hereditary angioedema gain an 87% attack reduction, Eli Lilly’s $2.3 B Ajax deal expands its oncology pipeline, and BridgeBio’s stock rises on Pfizer’s Vyndamax settlement, altering market share.
Ask SkimNews
